Ray Dalio Ultragenyx Pharmaceutical Inc. Transaction History

Bridgewater Associates, LP

  • $21.1 Billion
  • Q4 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$31.73 - $49.19 $23,924 - $37,089
-754 Reduced 6.62%
10,635 $508,000
Q3 2023

Nov 13, 2023
SELL
$34.92 - $46.66 $20,009 - $26,736
-573 Reduced 4.79%
11,389 $406,000
Q2 2023

Aug 11, 2023
SELL
$37.35 - $52.15 $63,719 - $88,967
-1,706 Reduced 12.48%
11,962 $551,000
Q1 2023

May 12, 2023
BUY
$36.99 - $48.71 $505,579 - $665,768
13,668 New
13,668 $548,000

Others Institutions Holding RARE

# of Institutions
344
Shares Held
86.6M
Call Options Held
675K
Put Options Held
846K
View Full List

About Ultragenyx Pharmaceutical Inc.

RARE Quotes by TradingView
  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $2.98B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track Ray Dalio's Portfolio

Track Ray Dalio Portfolio

Follow Ray Dalio (Bridgewater Associates, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email